NYSE:VOR - Vor Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $48.20
  • Forecasted Upside: 270.77 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$13.00
▼ -1.09 (-7.74%)

This chart shows the closing price for VOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vor Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VOR

Analyst Price Target is $48.20
▲ +270.77% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $48.20, with a high forecast of $60.00 and a low forecast of $19.00. The average price target represents a 270.77% upside from the last price of $13.00.

This chart shows the closing price for VOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Vor Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2021B. RileyReiterated RatingBuy$60.00High
3/24/2021B. RileyInitiated CoverageBuy$60.00Low
3/3/2021BarclaysInitiated CoverageOverweight$56.00High
3/2/2021Evercore ISIInitiated CoverageOutperform$48.00High
3/2/2021Stifel NicolausInitiated CoverageBuy$58.00High
3/2/2021The Goldman Sachs GroupInitiated CoverageSell$19.00High
(Data available from 7/23/2016 forward)
Vor Biopharma logo
Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $13.00
Low: $12.97
High: $14.41

50 Day Range

MA: $19.45
Low: $13.00
High: $22.56

52 Week Range

Now: $13.00
Low: $12.97
High: $63.62

Volume

250,285 shs

Average Volume

195,022 shs

Market Capitalization

$482.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vor Biopharma?

The following Wall Street research analysts have issued research reports on Vor Biopharma in the last year: B. Riley, Barclays PLC, Evercore ISI, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for VOR.

What is the current price target for Vor Biopharma?

5 Wall Street analysts have set twelve-month price targets for Vor Biopharma in the last year. Their average twelve-month price target is $48.20, suggesting a possible upside of 270.8%. B. Riley has the highest price target set, predicting VOR will reach $60.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $19.00 for Vor Biopharma in the next year.
View the latest price targets for VOR.

What is the current consensus analyst rating for Vor Biopharma?

Vor Biopharma currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VOR will outperform the market and that investors should add to their positions of Vor Biopharma.
View the latest ratings for VOR.

What other companies compete with Vor Biopharma?

How do I contact Vor Biopharma's investor relations team?

The company's listed phone number is 617 655 6580. The official website for Vor Biopharma is www.vorbiopharma.com.